Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmunityBio, Inc. on June 13, 2023. The filing discloses the entry into a material definitive agreement for debt financing and reports the results of the Company's Annual Meeting of Stockholders held on the same date.
Key Financial Metrics and Debt
- Debt Financing: Executed a $30.0 million variable-rate promissory note with Nant Capital, LLC, an entity affiliated with Executive Chairman Dr. Patrick Soon-Shiong.
- Interest Rate: Term SOFR plus 8.0% per annum.
- Drawdown Structure: The Company may request up to three advances of $10.0 million each.
- Net Proceeds: Expected to be approximately $29.85 million, net of a $150,000 origination fee (0.5%), assuming all advances are drawn.
- Maturity: Due on the earlier of December 31, 2023, or upon an Event of Default.
- Prepayment: Permitted at any time without premium or penalty upon five days' written notice.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins as this is a current report focused on specific events rather than periodic financial results.
Material Changes and Corporate Actions
The primary material change is the creation of a direct financial obligation of $30.0 million to fund pre-commercialization efforts, clinical development, research and development, capital expenditures, and general corporate purposes. Additionally, the Company held its Annual Meeting where 374,681,050 shares (approximately 86% of outstanding shares) were represented.
Outlook, Risks, and Management Commentary
- Use of Proceeds: Funds will support clinical development programs and may be used to license intellectual property or make acquisitions.
- Related Party Transaction: The lender is affiliated with the Company's Executive Chairman, which is a material related party transaction.
- Stockholder Vote Results:
- Director Election: All nine nominees were re-elected. Votes "For" ranged from approximately 334.5 million to 340.0 million, with "Withheld" votes ranging from approximately 597,000 to 6.1 million.
- Auditor Ratification: The appointment of Ernst & Young LLP was ratified with 374,132,354 votes "For" and 270,094 votes "Against".
Investor Verification Checklist
- Verify the specific terms and covenants of the Promissory Note filed as Exhibit 10.1.
- Confirm the Company's current cash position and ability to service the debt interest payments quarterly.
- Assess the impact of the related-party nature of the financing on future capital raising strategies.
- Review the Company's progress on clinical development programs to ensure the use of proceeds aligns with stated milestones.
- Monitor the maturity date of December 31, 2023, for potential refinancing needs or repayment obligations.